Compare

Stratec SE/€SBS

1D1W1M3M6MYTD1Y5YMAX

About Stratec SE

STRATEC SE, headquartered in Birkenfeld, Germany, specializes in designing and manufacturing fully automated analyzer systems, software, and smart consumables for the in-vitro diagnostics and life sciences sectors. Founded in 1979, the company operates through three segments: Instrumentation, Diatron, and Smart Consumables. The Instrumentation segment focuses on automated analyzer systems for clinical diagnostics and biotechnology clients; the Diatron segment offers systems and consumables for low-throughput hematology and clinical chemistry applications; and the Smart Consumables segment develops polymer-based consumables for diagnostics and medical applications. STRATEC primarily serves as an original equipment manufacturer (OEM), collaborating with diagnostic companies to develop products marketed under their brands. The company's global presence includes facilities in Switzerland, the United States, Romania, Hungary, Austria, and China. Its strategic positioning is reinforced by long-term partnerships with leading in-vitro diagnostics companies and a comprehensive technology portfolio that spans the entire value chain, from design and development to regulatory approval and production. (,)
Ticker
€SBS
Sector
Health
Primary listing
XETRA
Employees
1,383
Headquarters
Birkenfeld, Germany
Website
www.stratec.com

Stratec SE Metrics

BasicAdvanced
€318M
-
-€0.03
0.81
€0.60
2.32%

What the Analysts think about Stratec SE

Analyst ratings (Buy, Hold, Sell) for Stratec SE stock.
Analyst projections of the future price of Stratec SE stock.

Bulls say / Bears say

Selling Diatron removes a loss-making operation that was expected to contribute about €20 million of sales but roughly €10 million of adjusted EBIT losses in 2026. That should support group profitability, although the sale price is €10 million. (EQS News)
Analyzer-system sales rose 15.4% at constant currency in the first half, and the second-quarter adjusted EBIT margin more than doubled year on year to 11.9%. This points to better demand in core systems and potential operating leverage as volumes recover. (STRATEC)
Demand for lifecycle-management work remains high as customers face tougher cybersecurity and regulatory requirements. Several new systems are progressing towards production, with partner launches scheduled from mid-2027, offering a potential source of medium-term growth. (STRATEC)
After excluding Diatron, STRATEC expects 2026 sales to be only stable to slightly higher than the 2025 pro-forma level. That is a modest near-term growth outlook and puts more weight on the profitability gains from the disposal. (EQS News)
The disposal comes with a €44.1 million non-cash impairment in the third quarter and a further expected €4–9 million non-cash deconsolidation loss in the fourth. These charges will weigh on reported earnings, even if they do not represent equivalent cash outflows. (EQS News)
Service parts and consumables fell 11.9% at constant currency in the first half, while customer ordering remains volatile. The weaker mix weighed on first-half profitability, and management says inventories remain elevated, leaving the recovery in recurring sales uncertain. (STRATEC, StockAnalysis)
Data summarised monthly by Lightyear AI. Last updated on 2 Nov 2026.

Stratec SE Financial Performance

Revenues and expenses
Income statement
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
Net income
Profit margin

Stratec SE Earnings Performance

Company profitability
Earnings per share
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
Expected
Surprise
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.